



FINANCIAL TEAR SHEET

CORPORATE PROFILE

Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem's product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and a Phase 2 study in refractory indolent Non-Hodgkin's Lymphoma (iNHL). Verastem plans to share these clinical data with the U.S. Food and Drug Administration (FDA) with the goal of filing a New Drug Application (NDA) with the FDA during the first half of 2018. Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.

PRIMARY IR CONTACT

Brian Sullivan
 Corporate Development
Phone: 781-292-4214
Fax: 617-812-0059
E-mail:
bsullivan@verastem.com

STOCK PERFORMANCE

VSTM (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$3.14
Change (%)	▼ 0.51 (13.97%)
Volume	4,563,975
52 Week Low	\$1.08
Market Cap	\$127,136,703
Rolling EPS	-1.65
PE Ratio	N/A
Shares Outstanding	40,489,396

Data as of 12/15/17 4:00 p.m. ET



RECENT HEADLINES & EVENTS

12/15/17 - 9:18 a.m.

[Verastem Announces Pricing of Public Offering of Common Stock](#)

12/14/17 - 5:07 p.m.

[Verastem Announces Public Offering of Common Stock](#)

12/11/17 - 5:00 p.m.

[Verastem Announces the Presentation of Phase 1 Duvelisib Combination Data in T-Cell Lymphomas at the ASH 2017 Annual Meeting](#)

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
12/14/17	424B5
12/07/17	4
11/17/17	3
11/07/17	10-Q

CORPORATE GOVERNANCE

[Robert Forrester, LL.B.](#) President/Chief Executive Officer

[Dan Paterson](#) Chief Operating Officer

[Steven Bloom](#) Vice President, Corporate Development

[Julie Feder](#) Chief Financial Officer

[Diep Le, M.D, Ph.D.](#) Chief Medical Officer

[Jonathan Pachter, Ph.D.](#) Chief Scientific Officer

[Hagop Youssoufian, MSc, M.D.](#) Head of Hematology and Oncology Development

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed